Advanced search
Publication Cover
OncoImmunology Volume 12, 2023 - Issue 1
Submit an article Journal homepage
1,860
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations

Benjamin C. Parka School of Medicine, Vanderbilt University, Nashville, TN, USAView further author information
,
Sathya Narayananb Melanoma Institute Australia, The University of Sydney, Sydney, AustraliaView further author information
,
Alexander Gavralidisc Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USAView further author information
,
Fei Yed Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USAView further author information
,
Run Fand Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USAView further author information
,
Ryan J. Sullivanc Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USAView further author information
,
Genevieve Bolandc Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USAView further author information
,
Kerry L Reynoldsc Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USAView further author information
,
Justin M. Balkoe Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USAView further author information
,
Matteo S. Carlinob Melanoma Institute Australia, The University of Sydney, Sydney, Australia;f Crown Princess Mary Cancer Centre, Westmead Hospital, NSW, AustraliaView further author information
,
Georgina V. Longb Melanoma Institute Australia, The University of Sydney, Sydney, Australia;g Faculty of Medicine and Health, The University of Sydney, Sydney, Australia;h Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, AustraliaView further author information
,
Leyre Zubiric Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USAView further author information
,
Alexander M. Menziesb Melanoma Institute Australia, The University of Sydney, Sydney, Australia;g Faculty of Medicine and Health, The University of Sydney, Sydney, Australia;h Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, AustraliaView further author information
&
Douglas B. Johnsone Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USACorrespondence[email protected]
View further author information
 show all
Article: 2188719 | Received 04 Jan 2023, Accepted 05 Mar 2023, Published online: 08 Mar 2023

References

  • Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J ImmunoTher Cancer. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435.
  • Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw. 2020;18(3):230–8. doi:10.6004/jnccn.2020.0012.
  • Johnson DB, Chandra S, Sosman JA. 2018. Immune checkpoint inhibitor toxicity in 2018. JAMA: The Journal of the American Medical Association. 320(16):1702–1703. doi:10.1001/jama.2018.13995.
  • Postow MA, Sidlow R, Hellmann MD. 2018. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 378(2):158–168. doi:10.1056/NEJMra1703481.
  • Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728. doi:10.1001/jamaoncol.2018.3923.
  • Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. 2018. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 391(10124):933. doi:10.1016/S0140-6736(18)30533-6.
  • Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem J-E. 2019. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J ImmunoTher Cancer. 7(1):134. doi:10.1186/s40425-019-0617-x.
  • Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(1):80–91. doi:10.1161/CIRCULATIONAHA.118.034497.
  • Guidon AC, Burton LB, Chwalisz BK, Hillis J, Schaller TH, Amato AA, Betof Warner A, Brastianos PK, Cho TA, Clardy SL, et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J ImmunoTher Cancer. 2021;9(7). doi:10.1136/jitc-2021-002890.
  • Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. 2018. CHECKPOINT INHIBITOR IMMUNE THERAPY: systemic indications and ophthalmic side effects. Retina. 38(6):1063–1078. doi:10.1097/IAE.0000000000002181.
  • Abu-Sbeih H, Wang Y. Gastrointestinal tract adverse events. Adv Exp Med Biol. 2020;1244:247–253.
  • Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Himmel M, Rottapel R, Pope J, Hoa S, Tisseverasinghe A, et al. Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev. 2020;19(8):102595. doi:10.1016/j.autrev.2020.102595.
  • Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ. 2017. Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep. 19(3):21. doi:10.1007/s11886-017-0835-0.
  • Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon AR, et al. Defining cardiovascular toxicities of cancer therapies: an International cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280–299. doi:10.1093/eurheartj/ehab674.
  • Quach HT, Johnson DB, LeBoeuf NR, Zwerner JP, Dewan AK. 2021. Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol. 85(4):956–966. doi:10.1016/j.jaad.2020.09.054.
  • Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019;6(1):e48–57. doi:10.1016/S2352-3026(18)30175-3.
  • Wright JJ, Powers AC, Johnson DB. 2021. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 17(7):389–399. doi:10.1038/s41574-021-00484-3.
  • Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1–8. doi:10.1016/j.ejca.2016.12.001.
  • Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, et al. Clinical features and outcomes of immune checkpoint inhibitor–Associated AKI: a multicenter study. J Am Soc Nephrol. 2020;31(2):435–446. doi:10.1681/ASN.2019070676.
  • Herrmann SM, Perazella MA. 2020. Immune checkpoint inhibitors and immune-related adverse renal events. Kidney Int Rep. 5(8):1139–1148. doi:10.1016/j.ekir.2020.04.018.
  • Chan EW, Liu KQ, Chui CS, Sing C-W, Wong LY, Wong IC. 2015. Adverse drug reactions - examples of detection of rare events using databases. Br J Clin Pharmacol. 80(4):855–861. doi:10.1111/bcp.12474.
  • Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL. 2020. Diagnosis and management of rare immune-related adverse events. The Oncologist. 25(1):6–14. doi:10.1634/theoncologist.2019-0083.
  • Das S, Johnson DB. 2019. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J ImmunoTher Cancer. 7(1):306. doi:10.1186/s40425-019-0805-8.
  • Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, et al. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–Small cell lung cancer. JAMA Oncol. 2020;6(12):1952–1956. doi:10.1001/jamaoncol.2020.5012.
  • Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–1019. doi:10.1001/jamaoncol.2019.0393.
  • Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. 2022. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 19(4):254–267. doi:10.1038/s41571-022-00600-w.
  • Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–580. doi:10.1038/s41571-019-0218-0.
  • Wongvibulsin S, Pahalyants V, Kalinich M, et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis. J Am Acad Dermatol. 2022;86(3):563–572. doi:10.1016/j.jaad.2021.03.094.
  • Wang LX, Quach HT, Moodabigil NV, Davis EJ, Sosman JA, Dusestzina SB, Johnson DB. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. Cancer. 2020;126(2):322–328. doi:10.1002/cncr.32542.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.